TuttoCongressi
E-mail
Password
 Resta Collegato

Cerca per parole nell'archivio:
In archivio:
  • N° Relazioni: 478
  • N° Accessi Relaz.: 168905
Web Video
Portale Giovani Medici

   home   |   progetto   |   chi siamo   |   servizi   |   contatti   |   note legali Live Demo

   Mostra tutti | Mostra contenuti EasyRec   
01/03/2013
Apollon-Hall
09:00 - 10:30
TASK FORCE 9. NEW TRIALS DESIGN AND NEW THERAPIES
a9 
Any residual role of short-term trials using 6MWT as primary end-point for the approval of new PAH medications? Are there alternatives to traditional clinical worsening end-points in case current trials demonstrate feasibility issues?
b9 
Which is the best approach to compare sequential combination therapy with upfront combination therapy in PAH patients?
c9 
In which type of PAH patients is the benefit/risk ratio of tyrosine kinase inhibitors acceptable in PAH? What about additional new compounds?
d9 
Which are the new promising targets for PAH treatment (including genes and regenerative approaches)?
11:00 - 12:30
TASK FORCE 10. CTEPH
N. Kim 
Is pulmonary angiography still the gold standard for evaluating operability? What is the role of lung perfusion scan?
D. Jemkins 
What advancements or changes have been made in the surgical treatment of CTEPH? Is there a role for pulmonary angioplasty?
M. Delcroix 
What are the biological/pathological rationale and clinical evidence for medical treatment of CTEPH? Should approach to treatment factor in whether the patient is operable, deemed inoperable, or has persistent PH following endarterectomy?
H. Mayer 
How do we define successful treatment outcome in CTEPH?
14:00 - 15:30
TASK FORCE 11. PH DUE TO LEFT HEART DISEASES AND CHRONIC LUNG DISEASES
a11 
How to define out of proportion PH in left heart disease (TPG vs diastolic gradient; resting and exercise conditions)?
b11 
How to define out of proportion PH in COPD and ILD patients (including PFT and HRCT scan; resting and exercise conditions)?
c11 
Evidence for appropriate benefit to risk ratio of PAH approved drugs in patients with PH due to left heart or chronic lung disease?
d11 
Any specific targets for PH therapy in left heart or chronic lung diseases?
16:00 - 17:30
TASK FORCE 12. PEDIATRIC PH
a12 
Do we need specific definitions for PH, its classification and what is an acute response with acute vasodilator testing with pediatric patients, and is this the same regardless of the age of the child?
b12 
Are the prognostic parameters developed for adults valid also in pediatric patients?
c12 
Are treatment goals and end-points for clinical trials similar in adults and pediatric patients?
d12 
Are specific diagnostic and treatment algorithms required in pediatric patients?
17:30 - 18:00
FINAL REMARKS AND NEXT STEPS
N. Galiè 
Final remarks and next steps
 
Apollon-Hall-b
09:00 - 10:30
TASK FORCE 9. NEW TRIALS DESIGN AND NEW THERAPIES
a9 
Any residual role of short-term trials using 6MWT as primary end-point for the approval of new PAH medications? Are there alternatives to traditional clinical worsening end-points in case current trials demonstrate feasibility issues?
b9 
Which is the best approach to compare sequential combination therapy with upfront combination therapy in PAH patients?
c9 
In which type of PAH patients is the benefit/risk ratio of tyrosine kinase inhibitors acceptable in PAH? What about additional new compounds?
d9 
Which are the new promising targets for PAH treatment (including genes and regenerative approaches)?
11:00 - 12:30
TASK FORCE 10. CTEPH
N. Kim 
Is pulmonary angiography still the gold standard for evaluating operability? What is the role of lung perfusion scan?
D. Jemkins 
What advancements or changes have been made in the surgical treatment of CTEPH? Is there a role for pulmonary angioplasty?
M. Delcroix 
What are the biological/pathological rationale and clinical evidence for medical treatment of CTEPH? Should approach to treatment factor in whether the patient is operable, deemed inoperable, or has persistent PH following endarterectomy?
H. Mayer 
How do we define successful treatment outcome in CTEPH?
14:00 - 15:30
TASK FORCE 11. PH DUE TO LEFT HEART DISEASES AND CHRONIC LUNG DISEASES
a11 
How to define out of proportion PH in left heart disease (TPG vs diastolic gradient; resting and exercise conditions)?
b11 
How to define out of proportion PH in COPD and ILD patients (including PFT and HRCT scan; resting and exercise conditions)?
c11 
Evidence for appropriate benefit to risk ratio of PAH approved drugs in patients with PH due to left heart or chronic lung disease?
d11 
Any specific targets for PH therapy in left heart or chronic lung diseases?
16:00 - 17:30
TASK FORCE 12. PEDIATRIC PH
a12 
Do we need specific definitions for PH, its classification and what is an acute response with acute vasodilator testing with pediatric patients, and is this the same regardless of the age of the child?
b12 
Are the prognostic parameters developed for adults valid also in pediatric patients?
c12 
Are treatment goals and end-points for clinical trials similar in adults and pediatric patients?
d12 
Are specific diagnostic and treatment algorithms required in pediatric patients?
17:30 - 18:00
FINAL REMARKS AND NEXT STEPS
N. Galiè 
Final remarks and next steps
 
27/02/2013
Apollon-Hall
08:45 - 09:00
INTRODUCTION
Simonneau G.
Introduction
09:00 - 10:30
TASK FORCE 1. PATHOLOGY & PATHOBIOLOGY
Pathology & Pathobiology Task Force 1:
R. Tuder 
Does the pulmonary venous system play an important role in PAH and to what extent are PAH and PVOD part of the same spectrum of disease?
N. Morrell 
Are there distinct pathways in vascular cells in mild vs. severe pulmonary hypertension?
R. Tuder 
Cell proliferative changes in PAH distal pulmonary arteries: differences and similarities with traditional neoplastic disease
N. Morrell 
The role of inflammation in the initiation and progression of different PAH types
11:00 - 12:30
TASK FORCE 2. GENETICS AND GENOMIC
J. Newman 
Introduction
F. Soubrier 
What are the ethical issues that need discussion and implementation in PH?
W. K. Chung 
What are the signaling consequences of impaired BMPR2 gene function?
M. W. Geraci 
What application of genetic advances, such as miRNA, epigenetics for treatment and prevention of heritable PAH?
R. Trembath 
What are the co-factors that cause expression of desease in heritable PH, and what other genes may cause heritable PH?
14:00 - 15:30
TASK FORCE 3. DEFINITIONS AND CLASSIFICATIONS AND PARTICULARITIES OF DIFFERENT PAH SUBGROUPS
Definitions and Classifications and Particularities of Different PAH Subgroups Task Force 3:
I. Robbins 
C. Denton 
How do we define and handle "borderline" PH
M.Gatzoulis 
Congenital Heart Disease
G. Simonneau 
New Drugs and Toxins
R.Machado 
How to Classify Sickle Cell Disease ? Within Group 1
R. Souza 
How to Classify Sickle Cell Disease ? Within Group 5
16:00 - 17:30
TASK FORCE 4. PATHOPHYSIOLOGY (FOCUSING ON EXERCISE AND RV)
a4 
How to best assess RV contractility and function?
b4 
What are the underlying molecular mechanisms and metabolic characteristics of the failing RV in PAH?
c4 
What is the definition and relevance of exercise-induced PH?
d4 
What are the most relevant surrogate biomarkers of RV-PA function and their role in diagnosis and prognosis of PH?
 
Apollon-Hall-b
08:45 - 09:00
INTRODUCTION
G. Simonneau 
Introduction
09:00 - 10:30
TASK FORCE 1. PATHOLOGY & PATHOBIOLOGY
R. Tuder 
Does the pulmonary venous system play an important role in PAH and to what extent are PAH and PVOD part of the same spectrum of disease?
N. Morrell 
Are there distinct pathways in vascular cells in mild vs. severe pulmonary hypertension?
R. Tuder 
Cell proliferative changes in PAH distal pulmonary arteries: differences and similarities with traditional neoplastic disease
N. Morrell 
The role of inflammation in the initiation and progression of different PAH types
11:00 - 12:30
TASK FORCE 2. GENETICS AND GENOMIC
J. Newman 
Introduction
F. Soubrier 
What are the ethical issues that need discussion and implementation in PH?
W. K. Chung 
What are the signaling consequences of impaired BMPR2 gene function?
M. W. Geraci 
What application of genetic advances, such as miRNA, epigenetics for treatment and prevention of heritable PAH?
R. Trembath 
What are the co-factors that cause expression of desease in heritable PH, and what other genes may cause heritable PH?
14:00 - 15:30
TASK FORCE 3. DEFINITIONS AND CLASSIFICATIONS AND PARTICULARITIES OF DIFFERENT PAH SUBGROUPS
Definitions and Classifications and Particularities of Different PAH Subgroups Task Force 3:
C. Denton 
How do we define and handle "borderline" PH
M.Gatzoulis 
Congenital Heart Disease
G. Simonneau 
New Drugs and Toxins
R.Machado 
How to Classify Sickle Cell Disease ? Within Group 1
R. Souza 
How to Classify Sickle Cell Disease ? Within Group 5
16:00 - 17:30
TASK FORCE 4. PATHOPHYSIOLOGY (FOCUSING ON EXERCISE AND RV)
a4 
How to best assess RV contractility and function?
b4 
What are the underlying molecular mechanisms and metabolic characteristics of the failing RV in PAH?
c4 
What is the definition and relevance of exercise-induced PH?
d4 
What are the most relevant surrogate biomarkers of RV-PA function and their role in diagnosis and prognosis of PH?
 
28/02/2013
Apollon-Hall
09:00 - 10:30
TASK FORCE 5. EPIDEMIOLOGY AND REGISTRIES
a5 
Are PAH phenotypes changing in the modern management era?
b5 
Biases on survival analysis from registries
c5 
Is PAH survival improving in the modern management era?
d5 
Guidelines for registries implementation
11:00 - 12:30
TASK FORCE 6. DIAGNOSIS AND PROGNOSIS
M. Hoeper 
Should we include rest PVR in the definition of PH and how do we define and handle "borderline" PH?
D. Langleben 
What should be the upper limit of the PCWP, and what are the roles of fluid challenge and exercise hemodynamics in the identification of HFpEF patients?
D. Khanna 
How do we diagnose PAH in its early stages (including screening programs for high-risk populations)?
14:00 - 15:30
TASK FORCE 7. THERAPY - STANDARD OF CARE
a7 
Do we have additional information on the role of rehabilitation in PAH patients?
b7 
Should first-line combination therapy be the gold standard of severe WHO FC IV PAH (and what about other FC)?
c7 
How can we modify the current treatment algorithm including the new approved drugs?
d7 
Should we adapt the treatment algorithm to the different PAH types and to different countries (country organization)?
16:00 - 17:30
TASK FORCE 8. THERAPY ? GOALS
a8 
Are baseline and/or follow up prognostic predictors appropriate as treatment goals?
b8 
Is WHO FC III an inacceptable status in treated PAH patients?
c8 
Are treatment goals different in different PAH subgroups?
d8 
Any novel treatment goal from new technologies (CMR, biochemical markers, etc)?
 
Apollon-Hall-b
09:00 - 10:30
TASK FORCE 5. EPIDEMIOLOGY AND REGISTRIES
a5 
Are PAH phenotypes changing in the modern management era?
b5 
Biases on survival analysis from registries
c5 
Is PAH survival improving in the modern management era?
d5 
Guidelines for registries implementation
11:00 - 12:30
TASK FORCE 6. DIAGNOSIS AND PROGNOSIS
M. Hoeper 
Should we include rest PVR in the definition of PH and how do we define and handle "borderline" PH?
D. Langleben 
What should be the upper limit of the PCWP, and what are the roles of fluid challenge and exercise hemodynamics in the identification of HFpEF patients?
D. Khanna 
How do we diagnose PAH in its early stages (including screening programs for high-risk populations)?
14:00 - 15:30
TASK FORCE 7. THERAPY - STANDARD OF CARE
a7 
Do we have additional information on the role of rehabilitation in PAH patients?
b7 
Should first-line combination therapy be the gold standard of severe WHO FC IV PAH (and what about other FC)?
c7 
How can we modify the current treatment algorithm including the new approved drugs?
d7 
Should we adapt the treatment algorithm to the different PAH types and to different countries (country organization)?
16:00 - 17:30
TASK FORCE 8. THERAPY ? GOALS
a8 
Are baseline and/or follow up prognostic predictors appropriate as treatment goals?
b8 
Is WHO FC III an inacceptable status in treated PAH patients?
c8 
Are treatment goals different in different PAH subgroups?
d8 
Any novel treatment goal from new technologies (CMR, biochemical markers, etc)?
 

   home   |   progetto   |   chi siamo   |   servizi   |   contatti   |   note legali
Tuttocongressi ©1995 - 2026 | Via Dei Perfetti Ricasoli, 94-96 - 50127 Firenze  |  P.Iva 03755090481